Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Novartis’ blood disorder drug gets FDA approval for expanded use

The U.S. Food and Drug Administration expanded the use of Novartis AG’s low platelets drug Promacta to treat patients with a rare, genetic blood disorder.

Read More »

FDA approves Rigel Pharmaceuticals’ drug for rare bleeding disorder

The U.S. Food and Drug Administration approved Rigel Pharmaceuticals Inc.’s treatment for a rare bleeding disorder.

Read More »

Rigel Pharma Awaits FDA Approval for Tavalisse, Builds Commercial Org for Drug Launch

The first half of 2018 will be pivotal for Bay Area-based Rigel Pharmaceuticals Inc. as the company awaits regulatory approval for its rare blood disorder drug and builds out the internal infrastructure to commercialize the product.

Read More »

Novartis’ Promacta receives FDA breakthrough designation for new indication

Promacta received breakthrough therapy designation from the FDA for first-line treatment of SAA.

Read More »

FDA allows Alnylam to restart hemophilia treatment trials

The U.S. Food and Drug Administration allowed Alnylam Pharmaceuticals Inc. to restart clinical trials on a drug to treat patients with a rare bleeding disorder.

Read More »

Amgen Receives Positive CHMP Opinion To Expand Use Of Nplate

Amgen announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion to expand the current indication for Nplate.

Read More »

Shire to Consolidate 3,000+ Jobs Over 4 Years to 2 Massachusetts Sites

Dublin, Ireland-based Shire plans to consolidate more than 3,000 staffers spread out at over half-a-dozen locations across Massachusetts to two campuses in Cambridge and Lexington.

Read More »

Rigel’s bleeding disorder drug clears key trial

Rigel Pharmaceuticals Inc. said its experimental drug to treat a bleeding disorder met its main goal in the first of two late-stage trials.

Read More »

FDA approves Baxalta’s treatment for common bleeding disorder

The U.S. Food and Drug Administration on Tuesday approved Baxalta Inc’s Vonvendi, making it the first engineered protein-based treatment for the world’s most common inherited bleeding disorder. Vonvendi treats Willebrand disease, which is caused by the deficiency or defect in von Willebrand factor, a protein that is critical for blood clotting. The disease affects about […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!


Ad Right Bottom